Expression of integrin α v β 3 in medullary thyroid carcinoma.

Autor: de Vries LH; Department of Surgery, University Medical Center Utrecht, Heidelberglaan 100, 3584, CX Utrecht, The Netherlands., Lodewijk L; Department of Surgery, University Medical Center Utrecht, Heidelberglaan 100, 3584, CX Utrecht, The Netherlands., Pijnappel EW; Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, 3584, CX Utrecht, The Netherlands., van Diest PJ; Department of Pathology, University Medical Center Utrecht, Heidelberglaan 100, 3584, CX Utrecht, The Netherlands., Schepers A; Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2333, ZA Leiden, The Netherlands., Bonenkamp HJ; Department of Surgery, Radboud University Medical Center, Geert Grooteplein 8, 6525, GA Nijmegen, The Netherlands., van Engen-van Grunsven IA; Department of Pathology, Radboud University Medical Center, Geert Grooteplein 8, 6525, GA Nijmegen, The Netherlands., Kruijff S; Department of Surgery, University Medical Center Groningen, Hanzeplein 1, 9700, RB Groningen, The Netherlands., van Hemel BM; Department of Pathology, University Medical Center Groningen, Hanzeplein 1, 9700, RB Groningen, The Netherlands., Links TP; Department of Internal Medicine, University Medical Center Groningen, Hanzeplein 1, 9700. RB Groningen, The Netherlands., Nieveen van Dijkum EJ; Department of Surgery, Amsterdam University Medical Center, location University of Amsterdam, Cancer Center Amsterdam, Meibergdreef 9, 1105, AZ Amsterdam, The Netherlands., Eeden SV; Department of Pathology, Amsterdam University Medical Center, location University of Amsterdam, Cancer Center Amsterdam, Meibergdreef 9, 1105, AZ Amsterdam, The Netherlands., van Leeuwaarde RS; Department of Endocrine Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584, CX Utrecht, The Netherlands., Valk GD; Department of Endocrine Oncology, University Medical Center Utrecht, Heidelberglaan 100, 3584, CX Utrecht, The Netherlands., Keizer B; Department of Radiology & Nuclear Medicine, University Medical Center Utrecht, Heidelberglaan 100, 3584, CX Utrecht, The Netherlands., Borel Rinkes IH; Department of Surgery, University Medical Center Utrecht, Heidelberglaan 100, 3584, CX Utrecht, The Netherlands., Vriens MR; Department of Surgery, University Medical Center Utrecht, Heidelberglaan 100, 3584, CX Utrecht, The Netherlands.
Jazyk: angličtina
Zdroj: Future oncology (London, England) [Future Oncol] 2024 Aug 05, pp. 1-8. Date of Electronic Publication: 2024 Aug 05.
DOI: 10.1080/14796694.2024.2376511
Abstrakt: Aim: Tumor markers often remain elevated after intended curative resection of medullary thyroid carcinoma (MTC). The aim of this study was to determine the expression of α v β 3 , a promising theranostics target, in MTC and its metastases. Materials & methods: A v β 3 expression was analyzed in 104 patients using a tissue microarray and correlated with clinicopathological variables and survival. Results: Cytoplasmic α v β 3 positivity was seen in 70 patients and was associated with lymph node metastases at time of initial surgery. Membranous positivity was considered positive in 30 patients and was associated with sporadic MTC. Conclusion: A v β 3 was expressed in the cytoplasm of 67% of MTC patients. Membranous expression, which is presumably most relevant for the theranostic use of α v β 3 , was seen in 29%.
Databáze: MEDLINE